• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

Medical News Interviews

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Live Report from ASH:
Interleukin-2 For Acute Myeloid Leukemia In First Remission?

0
  • by alexperjescuadmin
  • in Oncology
  • — 10 Dec, 2007
Live Report from ASH:<br />Interleukin-2 For Acute Myeloid Leukemia In First Remission?
AudioMedica News
Live Report from ASH:
Interleukin-2 For Acute Myeloid Leukemia In First Remission?
Live Report from ASH:<br />Interleukin-2 For Acute Myeloid Leukemia In First Remission?
00:00 /
RSS Feed
Share
Link
Embed
//-->//>' class="input-embed input-embed-383"/>
Jonathan Kolitz
Jonathan Kolitz

JONATHAN KOLITZ, Monter Cancer Center, Lake Success, NY
GEORGE CANELLOS, Dana-Farber Cancer Institute

For patients with acute myeloid leukemia in first remission, new data suggests that there may be a benefit from interleukin-2. Derek Thorne got the interim results of this phase III trial from Jonathan Kolitz of Monter Cancer Center, Lake Success, NY, while George Canellos of the Dana-Farber Cancer Institute provided comment.

Live Report from ASH:<br />Interleukin-2 For Acute Myeloid Leukemia In First Remission?
[audio:https://www.audiomedica.com/podcasting/oncology/071209_jonathan_kolitz.mp3]
Share

Tags: acutecancerleukemiamyeloidNewspatientpodcastpodcastingreportreportstrial

You may also like...

  • Polygenic Risk Scores Could Help Predict Second Primary Breast Cancers—AUDIO JOURNAL OF ONCOLOGY Polygenic Risk Scores Could Help Predict Second Primary Breast Cancers—AUDIO JOURNAL OF ONCOLOGY 28 Mar, 2018
  • Young Women with HER2+ Early Breast Cancer Better with Mastectomy Young Women with HER2+ Early Breast Cancer Better with Mastectomy 24 Aug, 2016
  • Volker Heineman Cetuximab better than bevacizumab first-line in KRAS wild type expressing colorectal tumours 21 Jun, 2013
  • The TH3RESA study: TDM-1 doubles progression free survival in HER-2 positive refractory metastatic breast cancer. The TH3RESA study: TDM-1 doubles progression free survival in HER-2 positive refractory metastatic breast cancer. 19 Nov, 2013

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Previous story New Drug AMG 531 Effective in Splenectomized Patients with Chronic Immune Thrombocytopenic Purpura
  • Next story Live Report from ASH: Azacitidine ‘New Standard’ In High Risk Myelodysplastic Syndromes
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Ibrutinib: New Frontline Standard for Chronic…
    • Microbiome Diversity Key To Survival After…
    • Genomic-led AML Clinical Decision Making Within Seven Days
    • New Front Line Standard for Older Patients with…
    • First Line PARP Inhibition For Ovarian Cancer Assessed
  • Home
  • Oncology
  • Live Report from ASH:
    Interleukin-2 For Acute Myeloid Leukemia In First Remission?

© Copyright 2021 AudioMedica.com. Typegrid Theme by WPBandit.